Oral Chemotherapy Parity Laws Offer Some Financial Protection

Share this content:
Oral Chemotherapy Parity Laws Offer Some Financial Protection
Oral Chemotherapy Parity Laws Offer Some Financial Protection

MONDAY, Nov. 13, 2017 (HealthDay News) -- The adoption of state oral chemotherapy parity laws has improved financial protection for many patients, according to a study published online Nov. 9 in JAMA Oncology.

Stacie B. Dusetzina, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues conducted an analysis of health plan claims data from 2008 to 2012 for 63,780 adults living in one of 16 states that passed parity laws during the study period and who received anticancer drug treatment for which orally administered options were available.

The researchers found that there was a nonsignificant increase in the use of oral anticancer medication treatment as a proportion of all anticancer treatment from 18 to 22 percent. The proportion of prescription fills for orally administered therapy without copayment increased from 15 to 53 percent in plans subject to parity laws, compared with an increase from 12.3 to 18 percent in plans not subject to parity (P < 0.001). In plans subject to parity laws, estimated monthly out-of-pocket spending decreased by $19.44, $32.13, and $10.83 at the 25th, 50th, and 75th percentile and increased at the 90th and 95th percentiles ($37.19 and $143.25, respectively; all P < 0.001).

"While oral chemotherapy parity laws modestly improved financial protection for many patients without increasing total health care spending, these laws alone may be insufficient to ensure that patients are protected from high out-of-pocket medication costs," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

High Costs Associated With Physician Burnout, Attrition

High Costs Associated With Physician Burnout, Attrition

Economic loss at Stanford over two years expected to range from $15.5 million to $55.5 million

Insulin Doesn't Prevent Diabetes in Relatives of T1DM Patients

Insulin Doesn't Prevent Diabetes in Relatives of T1DM ...

Oral insulin doesn't delay onset in autoantibody-positive relatives of patients with type 1 diabetes

Workplace Sexual Harassment Ongoing in Women, Up for Men

Workplace Sexual Harassment Ongoing in Women, Up for ...

Women report more adverse effects after SH than men, but SH can trigger depression, anxiety in men

is free, fast, and customized just for you!

Already a member?

Sign In Now »